Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence

Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence

Combination therapy emerges as a fundamental scheme in cancer. Many targeted therapeutic agents are developed to be used with chemotherapy or radiation therapy to enhance drug efficacy and reduce toxicity effects. ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has...

Full description

Bibliographic Details
Main Authors: Nur Syahidah Nor Hisam, Azizah Ugusman, Nor Fadilah Rajab, Mohd Faizal Ahmad, Michael Fenech, Sze Ling Liew, Nur Najmi Mohamad Anuar
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Pharmaceutics
Subjects:
navitoclax (ABT-263)
anti-cancer
combination regimen
solid tumor
non-solid tumor
Online Access:https://www.mdpi.com/1999-4923/13/9/1353

Internet

https://www.mdpi.com/1999-4923/13/9/1353

Similar Items